Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares — Oct 2nd, 2024

NEW HAVEN, Conn., Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closin...

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine — Sep 30th, 2024

Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class,potent, orally administered Transient Receptor Potential Melastatin-3 (TRPM3) antagonist— a novel, highly selective, and non-opioid investigational tre...

Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock — Oct 3rd, 2024

Over the last year, a good number of insiders have significantly increased their holdings in Biohaven Ltd. (NYSE:BHVN). This is encouraging because it indicates that insiders are more optimistic about the company's prospects. Although we don't think shareholders should simply follow insid...

Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock — Oct 3rd, 2024

Over the last year, a good number of insiders have significantly increased their holdings in Biohaven Ltd. (NYSE:BHVN). This is encouraging because it indicates that insiders are more optimistic about the company's prospects. Although we don't think shareholders should simply follow insid...

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine — Sep 30th, 2024

Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class,potent, orally administered Transient Receptor Potential Melastatin-3 (TRPM3) antagonist— a novel, highly selective, and non-opioid investigational tre...

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares — Oct 1st, 2024

NEW HAVEN, Conn., Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing...

Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock — Oct 3rd, 2024

Over the last year, a good number of insiders have significantly increased their holdings in Biohaven Ltd. (NYSE:BHVN). This is encouraging because it indicates that insiders are more optimistic about the company's prospects. Although we don't think shareholders should simply follow insid...

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares — Oct 2nd, 2024

NEW HAVEN, Conn., Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closin...

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares — Oct 1st, 2024

NEW HAVEN, Conn., Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing...

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares — Oct 2nd, 2024

NEW HAVEN, Conn., Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closin...

Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy — Oct 7th, 2024

Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study. Continue reading View comments...

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine — Sep 30th, 2024

Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class,potent, orally administered Transient Receptor Potential Melastatin-3 (TRPM3) antagonist— a novel, highly selective, and non-opioid investigational tre...

Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy — Oct 7th, 2024

Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study. Continue reading View comments...

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares — Oct 2nd, 2024

NEW HAVEN, Conn., Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closin...

Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy — Oct 7th, 2024

Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study. Continue reading View comments...

Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy — Oct 7th, 2024

Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study. Continue reading View comments...

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares — Oct 2nd, 2024

NEW HAVEN, Conn., Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closin...

Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock — Oct 3rd, 2024

Over the last year, a good number of insiders have significantly increased their holdings in Biohaven Ltd. (NYSE:BHVN). This is encouraging because it indicates that insiders are more optimistic about the company's prospects. Although we don't think shareholders should simply follow insid...

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine — Sep 30th, 2024

Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class,potent, orally administered Transient Receptor Potential Melastatin-3 (TRPM3) antagonist— a novel, highly selective, and non-opioid investigational tre...

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares — Oct 2nd, 2024

NEW HAVEN, Conn., Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closin...

Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock — Oct 3rd, 2024

Over the last year, a good number of insiders have significantly increased their holdings in Biohaven Ltd. (NYSE:BHVN). This is encouraging because it indicates that insiders are more optimistic about the company's prospects. Although we don't think shareholders should simply follow insid...

Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More — Sep 26th, 2024

The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight as well. Here's a recap of the week’s most important stories: Biogen, UCB Lupus Study Data Biogen BIIB and partner UCB announced that the phase III PHOENYCS GO...

Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy — Oct 7th, 2024

Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study. Continue reading View comments...

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares — Oct 2nd, 2024

NEW HAVEN, Conn., Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closin...

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares — Oct 2nd, 2024

NEW HAVEN, Conn., Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closin...

BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal — Sep 24th, 2024

Shares of Biohaven Ltd. BHVN were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for the treatment of spinocerebellar ataxia (SCA), a rare and debilitating neurodegenerativ...

Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock — Oct 3rd, 2024

Over the last year, a good number of insiders have significantly increased their holdings in Biohaven Ltd. (NYSE:BHVN). This is encouraging because it indicates that insiders are more optimistic about the company's prospects. Although we don't think shareholders should simply follow insid...

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine — Sep 30th, 2024

Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class,potent, orally administered Transient Receptor Potential Melastatin-3 (TRPM3) antagonist— a novel, highly selective, and non-opioid investigational tre...

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares — Oct 1st, 2024

NEW HAVEN, Conn., Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing...

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine — Sep 30th, 2024

Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class,potent, orally administered Transient Receptor Potential Melastatin-3 (TRPM3) antagonist— a novel, highly selective, and non-opioid investigational tre...

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares — Oct 1st, 2024

NEW HAVEN, Conn., Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing...

Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock — Oct 3rd, 2024

Over the last year, a good number of insiders have significantly increased their holdings in Biohaven Ltd. (NYSE:BHVN). This is encouraging because it indicates that insiders are more optimistic about the company's prospects. Although we don't think shareholders should simply follow insid...

Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy — Oct 7th, 2024

Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study. Continue reading View comments...

Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock — Oct 3rd, 2024

Over the last year, a good number of insiders have significantly increased their holdings in Biohaven Ltd. (NYSE:BHVN). This is encouraging because it indicates that insiders are more optimistic about the company's prospects. Although we don't think shareholders should simply follow insid...

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares — Oct 1st, 2024

NEW HAVEN, Conn., Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing...

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine — Sep 30th, 2024

Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class,potent, orally administered Transient Receptor Potential Melastatin-3 (TRPM3) antagonist— a novel, highly selective, and non-opioid investigational tre...

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares — Oct 1st, 2024

NEW HAVEN, Conn., Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing...

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares — Oct 1st, 2024

NEW HAVEN, Conn., Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing...

Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More — Sep 26th, 2024

The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight as well. Here's a recap of the week’s most important stories: Biogen, UCB Lupus Study Data Biogen BIIB and partner UCB announced that the phase III PHOENYCS GO...

Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More — Sep 26th, 2024

The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight as well. Here's a recap of the week’s most important stories: Biogen, UCB Lupus Study Data Biogen BIIB and partner UCB announced that the phase III PHOENYCS GO...

Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock — Oct 3rd, 2024

Over the last year, a good number of insiders have significantly increased their holdings in Biohaven Ltd. (NYSE:BHVN). This is encouraging because it indicates that insiders are more optimistic about the company's prospects. Although we don't think shareholders should simply follow insid...

Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy — Oct 7th, 2024

Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study. Continue reading View comments...

Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy — Oct 7th, 2024

Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study. Continue reading View comments...

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares — Oct 1st, 2024

NEW HAVEN, Conn., Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing...

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares — Oct 2nd, 2024

NEW HAVEN, Conn., Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closin...